How have HCYTD shares performed in 2023?

H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2023 here .

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

H-CYTE Stock Price, News & Analysis (OTCMKTS:HCYTD)

$2.02

-1.98 (-49.50%)

(As of 07/11/2022)

Compare

Today's Range: $2.02
▼
$2.77
50-Day Range: $2.02
▼
$2.02
52-Week Range: $2.02
▼
$77.00

Volume: 400 shs
Average Volume: 103 shs
Market Capitalization: $521,160.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About H-CYTE Stock (OTCMKTS:HCYTD)

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

HCYTD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HCYTD Stock News Headlines

November 2, 2023 | morningstar.com

Hyatt Hotels Corp Class A H

June 14, 2023 | forbes.com

H-E-B Grocery Company

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

May 12, 2023 | marketwatch.com

10-K: H-CYTE, INC.

March 24, 2023 | seekingalpha.com

HCYT H-CYTE, Inc.

September 8, 2022 | finance.yahoo.com

H-CYTE Completes Acquisition of Jantibody

July 23, 2022 | apnews.com

H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

June 13, 2022 | finance.yahoo.com

H-CYTE Announces 1-for-1,000 Reverse Stock Split

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

March 6, 2022 | yahoo.com

Should You Refrigerate Peanut Butter?

March 6, 2022 | yahoo.com

Netflix’s new superhero show might be the weirdest thing you ever watch

March 4, 2022 | finance.yahoo.com

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

February 7, 2022 | nasdaq.com

H-CYTE Inc (HCYT)

January 11, 2022 | seekingalpha.com

H-CYTE signs letter of intent to acquire Catheter Precision

January 11, 2022 | finance.yahoo.com

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

December 6, 2021 | finance.yahoo.com

H-CYTE Names Michael Yurkowsky Chief Executive Officer

September 9, 2021 | au.finance.yahoo.com

Italian court seeks opinion on Berlusconi's health due to trial delays

September 8, 2021 | finance.yahoo.com

H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health

July 7, 2021 | ca.finance.yahoo.com

Jefferson Lines takes proactive steps toward crisis management with TSA I-STEP training

July 7, 2021 | in.finance.yahoo.com

Scanfil plc: Managers' transactions – Jokitalo

July 6, 2021 | finance.yahoo.com

H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health

July 1, 2021 | in.finance.yahoo.com

Constellium supplies advanced aluminium solutions for the electric Audi e-tron GT

July 1, 2021 | au.finance.yahoo.com

NetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon Magazine

June 29, 2021 | finance.yahoo.com

H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health

October 4, 2020 | msn.com

New Providence CEO: 'We have a responsibility and accountability to the community'

September 29, 2020 | feeds.benzinga.com

Robert Greif named Chief Executive Officer of H-CYTE

September 27, 2020 | marketwatch.com

Three Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QRO

See More Headlines

Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & Medical Instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:HCYTD
CUSIP: N/A
CIK: 1591165
Web: www.hcyte.com
Phone: (844) 633-6839
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,800,000.00
Net Margins: -450.40%
Pretax Margin: -450.40%
Return on Equity: N/A
Return on Assets: -777.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.12
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: $1.61 million
Price / Sales: 0.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($31.45) per share
Price / Book: -0.06

Miscellaneous

Outstanding Shares: 258,000
Free Float: 244,000
Market Cap: $521,160.00
Optionable: Not Optionable
Beta: 1.12

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Michael W. Yurkowsky (Age 50)
CEO & Director
Comp: $180k
Mr. Jeremy Daniel (Age 46)
Chief Financial Officer
Comp: $200k
Dr. Tanya Rhodes Ph.D. (Age 61)
Chief Scientific Officer
Comp: $252k
Mr. Jeffery Wright CPA (Age 39)
CPA, Controller & Principal Accounting Officer

Key Competitors

View All Competitors

HCYTD Stock Analysis - Frequently Asked Questions

How have HCYTD shares performed in 2023?: H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02.
View the best growth stocks for 2023 here.
How do I buy shares of H-CYTE?: Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:HCYTD) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial